Mizuho Starts Coverage on Pulse Biosciences With Outperform, $25 Target
Mizuho has initiated coverage of Pulse Biosciences (PLSE) with an Outperform rating and a $25 price target, implying roughly 75% upside from the current share price of $13.62. The research call highlights positive physician feedback supporting rapid adoption of the company’s nanosecond pulsed field ablation (nsPFA or nPulse) technology after FDA cl…